CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology
Inobrodib is a pioneering drug targeting twin tumour drivers…
Biocomposites to host Infection Management Symposium on new best practice framework for treating diabetic foot infections at Wounds UK
Consensus group of clinicians have developed a framework…
Novo Holdings acquires KabaFusion from Pritzker Private Capital. KabaFusion’s clinician-led management team will remain significant investors in the business alongside Novo Holdings
Novo Holdings, a leading healthcare investment firm, announced…
Novo Nordisk Foundation grants DKK 25 million ($3.3 million) for completion of clinical trial to improve treatment outcomes for people with critical limb ischaemia
The grant will enable leading international researchers to complete…
AMSilk Invited to Participate in VISION 2045 Summit
Leaders from across the world will convene at VISION 2045 Summit…
Enzyre closes Series A financing round of EUR 12M to advance pioneering diagnostic technology platform for hemophilia patients
Funds will be used to accelerate development of proprietary ambulant…
ImaginAb Announces First Patient Dosed in Australia in Phase IIb iPREDICT Trial
Los Angeles, California, USA, October 25th, 2022 – ImaginAb…
Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON)
alfapump achieves pre-specified primary effectiveness endpoints…
Gadeta Appoints Scientific Advisory Board and Provides Business Update
Utrecht, Netherlands and Boston, Mass., 20 October 2022: Gadeta…
Enhanc3D Genomics raises £10 million in Series A financing to advance GenLink3D proprietary technology platform
Cambridge, UK, 20th October 2022: Enhanc3D Genomics (“Enhanc3D”),…
STORM Therapeutics to present new data on its lead program STC-15 at the 34th EORTC-NCI-AACR Symposium and the 37th SITC Meeting
STC-15 is an oral small molecule inhibitor of the RNA methyltransferase…
ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors
Targeting final lead therapy selection, neutralizing all known…
AMSilk Relocate Offices to Support Expansion Plans
The purpose-built offices will support its production of game-changing…
Neuraxpharm launches European campaign to increase awareness of medical cannabis
Neuraxpharm launches European campaign to increase awareness…
Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering
AMSTERDAM, THE NETHERLANDS October 18th, 2022 — Synaffix B.V.…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
